Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZG5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,664
Award facts
- Contract value 100% obligated
- $38,663.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $38,663.83 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Trikafta 100-50-75 mg/150 mg tablets (84-count unit). This delivery order, issued on January 21, 2026, with an ultimate completion date of January 22, 2026, carries no set-aside designation and represents a routine pharmaceutical supply transaction executed under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA. The product being delivered is a branded cystic fibrosis treatment medication, reflecting DMS Pharmaceutical Group's established role as a critical supplier within the federal military pharmaceutical supply chain.
This delivery order operates under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract designated SPE2DR, awarded November 13, 2025, under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.999 billion ceiling value through December 31, 2036. The PPV-G GEN V represents a $30.3 billion federal acquisition strategy designed to consolidate pharmaceutical procurement across Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's demonstrated performance on numerous delivery orders since contract award, combined with its comprehensive product portfolio spanning specialty biologics, oncology treatments, and routine pharmaceuticals, establishes the company as a qualified regional prime vendor capable of fulfilling diverse pharmaceutical requirements for military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FCZG5?
SPE2DR26FCZG5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FCZG5 worth?
The government has obligated $38,664 on SPE2DR26FCZG5.
Is contract SPE2DR26FCZG5 an order under another contract?
Yes. SPE2DR26FCZG5 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZG5 competed?
The extent of competition for SPE2DR26FCZG5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award